Nexalin targets Q2 FDA Q-Submission update for Alzheimer’s De Novo pathway

• Nexalin set plans to finalize design of an FDA Alzheimer’s symptom-reduction trial to support a De Novo application for its non-invasive DIFS brain-stimulation device.
• Clinical design is being aligned to FDA guidance on clinically relevant primary and secondary endpoints for treatment response in Alzheimer’s patients.
• Management targets submission of an amended FDA Q-Submission in Q2 2026.
• China collaboration will continue with Professor Yi Tang to leverage ongoing real-world clinical data in Alzheimer’s patients to inform global clinical strategy.
• Program focus centers on stabilizing disrupted brain networks to reduce symptoms, with an aim to slow or delay admissions to hospitals or memory care centers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604151000PRIMZONEFULLFEED9690406) on April 15, 2026, and is solely responsible for the information contained therein.